130 related articles for article (PubMed ID: 18318468)
1. Design, synthesis, and biological evaluation of AT1 angiotensin II receptor antagonists based on the pyrazolo[3,4-b]pyridine and related heteroaromatic bicyclic systems.
Cappelli A; Nannicini C; Gallelli A; Giuliani G; Valenti S; Mohr Gl; Anzini M; Mennuni L; Ferrari F; Caselli G; Giordani A; Peris W; Makovec F; Giorgi G; Vomero S
J Med Chem; 2008 Apr; 51(7):2137-46. PubMed ID: 18318468
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, structural studies, biological evaluation, and computational simulations of novel potent AT(1) angiotensin II receptor antagonists based on the 4-phenylquinoline structure.
Cappelli A; Pericot Mohr Gl Gl; Gallelli A; Rizzo M; Anzini M; Vomero S; Mennuni L; Ferrari F; Makovec F; Menziani MC; De Benedetti PG; Giorgi G
J Med Chem; 2004 May; 47(10):2574-86. PubMed ID: 15115399
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological activity of 6-substituted carbamoyl benzimidazoles as new nonpeptidic angiotensin II AT₁ receptor antagonists.
Zhang J; Wang JL; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Bioorg Med Chem; 2012 Jul; 20(14):4208-16. PubMed ID: 22727371
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of 6-substituted aminocarbonyl benzimidazole derivatives as nonpeptidic angiotensin II AT1 receptor antagonists.
Wang JL; Zhang J; Zhou ZM; Li ZH; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Eur J Med Chem; 2012 Mar; 49():183-90. PubMed ID: 22309912
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptidic angiotensin II AT₁ receptor antagonists derived from 6-substituted aminocarbonyl and acylamino benzimidazoles.
Zhang J; Wang JL; Yu WF; Zhou ZM; Tao WC; Wang YC; Xue WZ; Xu D; Hao LP; Han XF; Fei F; Liu T; Liang AH
Eur J Med Chem; 2013 Nov; 69():44-54. PubMed ID: 24007859
[TBL] [Abstract][Full Text] [Related]
6. Discovery of a series of imidazo[4,5-b]pyridines with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Filzen GF; Flynn D; Bigge CF; Chen J; Davis JA; Dudley DA; Edmunds JJ; Esmaeil N; Geyer A; Heemstra RJ; Jalaie M; Ohren JF; Ostroski R; Ellis T; Schaum RP; Stoner C
J Med Chem; 2011 Jun; 54(12):4219-33. PubMed ID: 21557540
[TBL] [Abstract][Full Text] [Related]
7. Further studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.
Cappelli A; Pericot Mohr Gl; Giuliani G; Galeazzi S; Anzini M; Mennuni L; Ferrari F; Makovec F; Kleinrath EM; Langer T; Valoti M; Giorgi G; Vomero S
J Med Chem; 2006 Nov; 49(22):6451-64. PubMed ID: 17064065
[TBL] [Abstract][Full Text] [Related]
8. Revelation on the potency of α(1) -blockers - parallel blockade of angiotensin II receptor: a new finding.
Yadav MR; Gandhi HP; Naik PP; Giridhar R
Pharm Biol; 2012 Apr; 50(4):439-42. PubMed ID: 22136253
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and selective cyclooxygenase-2 (COX-2) inhibitory activity of a series of novel bicyclic pyrazoles.
Ranatunge RR; Garvey DS; Janero DR; Letts LG; Martino AM; Murty MG; Richardson SK; Young DV; Zemetseva IS
Bioorg Med Chem; 2004 Mar; 12(6):1357-66. PubMed ID: 15018908
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II--AT1 receptor antagonists: design, synthesis and evaluation of substituted carboxamido benzimidazole derivatives.
Shah DI; Sharma M; Bansal Y; Bansal G; Singh M
Eur J Med Chem; 2008 Sep; 43(9):1808-12. PubMed ID: 18158200
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ.
Casimiro-Garcia A; Heemstra RJ; Bigge CF; Chen J; Ciske FA; Davis JA; Ellis T; Esmaeil N; Flynn D; Han S; Jalaie M; Ohren JF; Powell NA
Bioorg Med Chem Lett; 2013 Feb; 23(3):767-72. PubMed ID: 23265881
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase inhibitors. Part 3: Design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-dihydropyridazinones with anti-inflammatory and bronchodilatory activity.
Ochiai K; Takita S; Eiraku T; Kojima A; Iwase K; Kishi T; Fukuchi K; Yasue T; Adams DR; Allcock RW; Jiang Z; Kohno Y
Bioorg Med Chem; 2012 Mar; 20(5):1644-58. PubMed ID: 22336247
[TBL] [Abstract][Full Text] [Related]
13. Substituted pyrazolo[3,4-b]pyridines as potent A1 adenosine antagonists: synthesis, biological evaluation, and development of an A1 bovine receptor model.
Tuccinardi T; Schenone S; Bondavalli F; Brullo C; Bruno O; Mosti L; Zizzari AT; Tintori C; Manetti F; Ciampi O; Trincavelli ML; Martini C; Martinelli A; Botta M
ChemMedChem; 2008 Jun; 3(6):898-913. PubMed ID: 18338422
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, nicotinic acetylcholine receptor binding affinities, and molecular modeling of constrained epibatidine analogues.
Wei ZL; Petukhov PA; Xiao Y; Tückmantel W; George C; Kellar KJ; Kozikowski AP
J Med Chem; 2003 Mar; 46(6):921-4. PubMed ID: 12620069
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel pyrazolo[1,5-a]pyridine-based EP
Nishigaya Y; Umei K; Saito Y; Watanabe H; Kondo T; Kondo A; Kawamura N; Tatani K; Kohno Y; Tanaka N; Seto S
Bioorg Med Chem Lett; 2017 Sep; 27(17):4044-4050. PubMed ID: 28784294
[TBL] [Abstract][Full Text] [Related]
16. New NO-releasing pharmacodynamic hybrids of losartan and its active metabolite: design, synthesis, and biopharmacological properties.
Breschi MC; Calderone V; Digiacomo M; Macchia M; Martelli A; Martinotti E; Minutolo F; Rapposelli S; Rossello A; Testai L; Balsamo A
J Med Chem; 2006 Apr; 49(8):2628-39. PubMed ID: 16610806
[TBL] [Abstract][Full Text] [Related]
17. Substituted pyrazolo[3,4-b]pyridines as human A1 adenosine antagonists: developments in understanding the receptor stereoselectivity.
Tuccinardi T; Zizzari AT; Brullo C; Daniele S; Musumeci F; Schenone S; Trincavelli ML; Martini C; Martinelli A; Giorgi G; Botta M
Org Biomol Chem; 2011 Jun; 9(12):4448-55. PubMed ID: 21390354
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase inhibitors. Part 4: design, synthesis and structure-activity relationships of dual PDE3/4-inhibitory fused bicyclic heteroaromatic-4,4-dimethylpyrazolones.
Ochiai K; Takita S; Kojima A; Eiraku T; Ando N; Iwase K; Kishi T; Ohinata A; Yageta Y; Yasue T; Adams DR; Kohno Y
Bioorg Med Chem Lett; 2012 Sep; 22(18):5833-8. PubMed ID: 22884989
[TBL] [Abstract][Full Text] [Related]
19. Pharmacophore, drug metabolism, and pharmacokinetics models on non-peptide AT1, AT2, and AT1/AT2 angiotensin II receptor antagonists.
Berellini G; Cruciani G; Mannhold R
J Med Chem; 2005 Jun; 48(13):4389-99. PubMed ID: 15974591
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological activity of 2-alkylbenzimidazoles bearing a N-phenylpyrrole moiety as novel angiotensin II AT1 receptor antagonists.
Xu JY; Zeng Y; Ran Q; Wei Z; Bi Y; He QH; Wang QJ; Hu S; Zhang J; Tang MY; Hua WY; Wu XM
Bioorg Med Chem Lett; 2007 May; 17(10):2921-6. PubMed ID: 17412584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
